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Background: Prophylactic mesh-augmented reinforcement during closure of abdomi-
nal wall incisions has been proposed in patients with increased risk for development of 
incisional hernias (IHs). As part of the BioMesh consensus project, a systematic literature 
review has been performed to detect those studies where MAR was performed with a 
non-permanent absorbable mesh (biological or biosynthetic).
Methods: A computerized search was performed within 12 databases (Embase,
Medline, Web-of-Science, Scopus, Cochrane, CINAHL, Pubmed publisher, Lilacs,
Scielo, ScienceDirect, ProQuest, Google Scholar) with appropriate search terms.
Qualitative evaluation was performed using the MINORS score for cohort studies and 
the Jadad score for randomized clinical trials (RCTs).
Results: For midline laparotomy incisions and stoma reversal wounds, two RCTs, two 
case–control studies, and two case series were identified. The studies were very het-
erogeneous in terms of mesh configuration (cross linked versus non-cross linked), mesh 
position (intraperitoneal versus retro-muscular versus onlay), surgical indication (gastric 
bypass versus aortic aneurysm), outcome results (effective versus non-effective). After 
qualitative assessment, we have to conclude that the level of evidence on the efficacy 
and safety of biological meshes for prevention of IHs is very low. No comparative studies 
were found comparing biological mesh with synthetic non-absorbable meshes for the 
prevention of IHs.
Conclusion: There is no evidence supporting the use of non-permanent absorbable 
mesh (biological or biosynthetic) for prevention of IHs when closing a laparotomy in high-
risk patients or in stoma reversal wounds. There is no evidence that a non-permanent 
absorbable mesh should be preferred to synthetic non-absorbable mesh, both in clean 
or clean-contaminated surgery.
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iNTRODUCTiON
Prophylactic mesh-augmented reinforcement during closure of 
abdominal wall incisions has been proposed in patients at high 
risk for incisional hernia (IH). Several randomized clinical trials 
(RCTs) have been published on the use of prophylactic mesh in 
patients undergoing aortic aneurysm surgery (1–4), obesity sur-
gery (3, 5–7), stoma creation (8–14), in colorectal cancer patients 
(15, 16), or other high-risk patients (17, 18). The recently published 
guidelines of the European Hernia Society have provided the fol-
lowing weak recommendation: “Prophylactic mesh augmentation 
for an elective midline laparotomy in high-risk patients in order to 
reduce the risk of incisional hernias is suggested.” Due to the lack 
of sufficient data, no recommendations on the type of mesh, the 
optimal mesh position, or the optimal mesh fixation technique 
could be made (19). Although prophylactic mesh-augmented 
reinforcement has been performed safely in clean-contaminated 
setting, one concern is the potential short- or long-term harms 
by implantation of a permanent mesh (20). Application of a 
non-permanent absorbable for prophylactic mesh-augmented 
reinforcement might therefore hold some benefit if these meshes 
will be as effective as permanent meshes.
A systematic literature review has been performed to detect 
those studies where prophylactic mesh-augmented reinforcement 
was performed with a non-permanent absorbable biological or 
biosynthetic mesh and provide guidance for future research on 
the use of biological or biosynthetic meshes.
MeTHODS
Protocol
The systematic search was part of the BioMesh consensus project. 
This project, initiated by Ferdinand Köckerling, gathered surgical 
expertise in a working group to provide a summary on the use of 
non-permanent absorbable biological or biosynthetic meshes in 
different indications. During a consensus meeting in Berlin on 
January 27, 2016, the working group decided in consensus on the 
statements and conclusions derived from the level of evidence for 
each indication. This manuscript reports on the review of the use 
of non-permanent absorbable biological or biosynthetic meshes 
for the prevention of IHs.
eligibility Criteria
Inclusion criteria: because of the paucity of available studies on 
prophylactic mesh-augmented reinforcement with biological or 
biosynthetic mesh for the prevention of IHs, no limitation, to the 
study design, length of follow-up, or number of included patients, 
was used.
Exclusion criteria: prevention of parastomal hernias were 
excluded because this was part of a separate search within the 
BioMesh study group (21).
information Sources
A computerized search was performed within 12 databases 
(Embase, Medline, Web-of-Science, Scopus, Cochrane, CINAHL, 
Pubmed publisher, Lilacs, Scielo, ScienceDirect, ProQuest, 
Google Scholar) on June 25, 2015.
Search
The biomedical librarian of the Erasmus University Medical 
Centre, Rotterdam, The Netherlands performed the search, 
and the search strategy is provided in Section “Addendum 1” in 
Appendix.
Study Selection
From the search, only the studies reporting on the use of a non-
permanent absorbable biological or biosynthetic mesh were 
retained. Studies written in English, Dutch, French, and Spanish 
were considered.
Data Collection Process
Two authors (Filip Etienne Muysoms and An Jairam) indepen-
dently screened all records retrieved upon application of the 
search strategy by title and abstract. The full text of all retained 
records was screened for eligibility. The references of all review 
articles found were cross-checked for additional eligible records.
Data items
The following data were extracted by two authors independently 
and cross-checked: type of study, number of patients included, 
patient characteristics, indication for surgery, type of biological 
mesh, position of the mesh, method of mesh fixation, length 
of follow-up, and outcome measures (hernias, seroma, wound 
infections, burst abdomen). Primary outcome was IH incidence, 
and secondary outcomes were postoperative seroma, wound 
infection, and burst abdomen.
Quality Assessment of individual Studies
Qualitative evaluation was performed using the MINORS score 
for non-randomized studies (22) and the Jadad score for RCTs 
(23). Additionally, the quality of evidence across the RCTs was 
done using the GRADE Pro software.1
Statistical Analysis
A meta-analysis of the outcome from the RCTs detected was per-
formed for relevant outcomes: IH, seroma, wound infections, and 
burst abdomen. Meta-analysis was performed using the Review 
Manager 5.3 software (Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2013). Our outcomes were 
expressed as risk ratios (RRs) with 95% confidence intervals 
(CIs) to estimate the pooled effect size and p-value. All tests were 
two-sided.
ReSULTS
Study Selection
The PRISMA flow diagram of our search is illustrated in Figure 1. 
Six studies were retained after the screening and sift for eligibil-
ity. Four studies included patients with midline laparotomy 
(2, 7, 24, 25), and two studies investigated the prevention of IHs 
after stoma reversal (26, 27).
1 www.gradepro.org 
FiGURe 1 | PRiSMA flow diagram of a systematic review on the use of biological mesh for prevention of incisional hernias.
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Study Characteristics
Midline Laparotomy
Our literature review revealed four studies where a biological 
mesh was used to prevent IHs in high-risk patients. Details of 
the study characteristics and quality assessment (MINORS 
score, Jadad score) are shown in the summary of evidence table 
(Table 1). A small cohort study on eight patients that underwent a 
midline laparotomy for cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy (HIPEC) described short-term 
outcome using an intraperitoneal biological mesh (24). In a 
prospective non-randomized case–control study, obese patients 
operated for a gastric bypass through a midline laparotomy were 
either treated with an intraperitoneal biological mesh (n = 59) or 
primary suture closure (n = 75). A significant reduction in the 
number of IHs by prophylactic mesh was reported [2.3% (90% CI: 
2.31–6.86) versus 17.7% (90% CI: 7.92–27.52), p = 0.014] (25). In 
an RCT in obese patients undergoing a gastric bypass operation 
through a midline laparotomy, patients were randomized between 
an intraperitoneal biological mesh (n = 185) and primary suture 
closure (n = 195). This adequately powered RCT, did not show 
any benefit for prophylactic mesh concerning the risk for IH at 
24 months (17.3 versus 19.5%, p = 0.60), but did show a significant 
higher number of wound infections and wound seroma in the 
mesh group (7). In an RCT of aortic aneurysm patients, midline 
laparotomy closure with an onlay biologic mesh (n =  20) was 
compared to primary suture closure (n = 20) (2). The study was 
not powered with a sample size calculation, but the follow up was 
adequate in length (36 months) and methodology (systematic CT 
TABLe 1 | Summary of evidence table of a systematic review on the use of biological mesh for the prevention of incisional hernias after midline laparotomy.
Reference Study type Quality 
assessment
N (mesh/
no mesh)
Patient characteristics intervention Comparison Length of  
follow-up (months)
Outcome measure
Boutros  
et al. (24)
Non-comparative 
case series
MINORS  
score 5/16
8/– Midline laparotomy for 
cytoreductive surgery 
and HIPEC in peritoneal 
carcinoma patients
Intraperitoneal 
Surgisis 
20 cm × 20 cm fixed 
with PDS sutures
– Mean 6.3 Seven patients had no abdominal wall morbidity. 
One patient had an incisional hernia and  
entero-cutaneous fistula following re-laparotomy 
2 weeks after the primary operation
General comments: very low MINORS score of this case series. Follow-up inadequate to make conclusion about incisional hernia rate
Funding: no direct funding; speakers fee from Cook
Study registration: no
Llaguna  
et al. (25)
Prospective  
case–control  
study
MINORS  
score 19/24
134  
(59/75)
Patients undergoing gastric 
bypass surgery with midline 
laparotomy
Intraperitoneal 
Alloderm 16-cm long 
and 6-cm wide, fixed 
with PDS sutures
Sutured with PDS no 
1, running suture
Mean 17.3 Incisional hernia: mesh: 1/44 (2%); no mesh: 
11/62 (18%); p = 0.014 (OR 0.06)
General comments: prospective single surgeon non-randomized study, with adequate follow-up. Statistical significant differences on the number of patients with some confounding factors were seen: prior abdominal 
surgery, postoperative BMI
Funding: not mentioned
Study registration: no
Sarr  
et al. (7)
RCT JADAD  
score 2/5
402 
(185/195)
Patients undergoing gastric 
bypass surgery with midline 
laparotomy
Intraperitoneal 
Surgisis 8-cm wide 
fixed with PDS 
sutures
Suture  
non-absorbable and 
absorbable, running 
suture
24 Incisional hernia: mesh: 32/185 (17.3%); no mesh: 
38/195 (19.5%); p = 0.60; wound infections: 
11.9% versus 3.6% (p < 0.003); wound seroma: 
4.9% versus 0.5% (p < 0.01)
General comments: open label RCT with adequate sample calculation and power. Showed no difference in incisional hernia rate. The number of clinically relevant wound infections and wound seroma was significant 
higher in the Mesh group
Funding: industry-funded study (Cook Biotech, Inc., West Lafayette, IN, USA)
Study registration: www.ClinicalTrials.gov NCT00274625
Bali  
et al. (2)
RCT JADAD  
score 1/5
40  
(20/20)
Elective midline laparotomy 
for AAA repair
Onlay periguard 
8-cm wide fixed 
with non-absorbable 
sutures
Sutured with PDS no 
1, running suture
36 Incisional hernia: mesh: 0/20 (0%); no mesh: 6/20 
(32%); estimate freedom of incisional hernia was 
significantly higher for the mesh group (p < 0.008)
General comments: small open label RCT, no sample size calculation. Prophylactic mesh was effective and safe
Funding: not mentioned
Study registration: no
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TABLe 2 | Summary of evidence table of a systematic review on the use of biological mesh for prevention of incisional hernias after stoma reversal.
Reference Study type Quality  
assessment
N  
(mesh/no mesh)
Patient  
characteristics
intervention Comparison Length of 
follow-up
Outcome 
measure
Bhangu  
et al. (26)
Non-comparative  
case series
MINORS  
score 4/16
7/– Patients with a 
temporary ileostomy 
needing stoma closure
Intraperitoneal 
Strattice 3-cm 
overlap fixed with 
PDS sutures
– 30 days One superficial 
wound infection. 
No early hernias
General comments: very low MINORS score of this case series. Follow-up inadequate to make conclusion about incisional hernia rate. This study is a pilot study on 
the safety of the technique, before starting a large RCT
Funding: industry-funded study
Study registration: part of the ROCCS study: www.ClinicalTrials.gov NCT02238964
Maggiori  
et al. (27)
Matched  
case–control  
study
MINORS  
score 15/24
94 (30/64) Closure of a diverting 
ileostomy following 
rectal cancer resection
Retro-muscular 
Meccellis mesh 
10 cm × 10 cm, 
fixed with prolene 
sutures
Two layer 
continuous 
suture of 
anterior and 
posterior fascia 
with Vicryl 1
1 year Radiological 
incisional hernia 
rate mesh: 1/30 
(3%); no mesh: 
12/64 (19%) 
p = 0.043
General comments: Significant reduction of the number of incisional hernias at the stoma wound diagnosed with CT scan. No difference in morbidity
Funding: industry-funded study
Study registration: no
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scan evaluation). A highly significant protective effect of the mesh 
was shown, with no hernias in the mesh group and 32% in the 
non-mesh group [cumulative freedom of IH at 36 months was 
100 versus 74.4% (p < 0.008)] (2).
Stoma Reversal Wound
Our literature review revealed two studies in which a biologi-
cal mesh was used to prevent IHs after reversal of a temporary 
ileostomy. Details of the studies are shown in the summary of 
evidence table (Table 2). In a pilot study with a limited patient 
population (n = 7), the feasibility of an intraperitoneal prophy-
lactic mesh was investigated in terms of safety in the short term 
(27). The second report was a matched case–control study of 30 
patients that received a retro-muscular prophylactic biological 
mesh, compared to 64 matched patients with suture closure of 
the stoma wound. At 1-year follow-up with CT scan, the number 
of patients with IH was significantly lower for the mesh group 
(p = 0.043).
Meta-analysis
The pooled analysis for the outcome IH showed no statistical dif-
ferences between groups (RR 0.38, 95% CI 0.04–3.83; p = 0.41). 
The forest plots of the meta-analysis of the two RCTs on preven-
tion of midline laparotomy IHs, and the secondary outcomes are 
shown in Figure 2.
DiSCUSSiON
Midline Laparotomy
Overall, the Level of Evidence on the efficacy of biological mesh to 
prevent IHs is very low. Moreover, the study with the highest level 
of evidence and lowest risk of bias did not show any advantage 
in reducing IHs by prophylactic intraperitoneal biological mesh 
in patients undergoing a midline laparotomy for performing 
gastric bypass surgery (7). On the contrary, it did show a higher 
number of wound complications after the use of the prophylactic 
mesh. Another study regarding gastric bypass patients did show 
a benefit, but this study was non-randomized and had a high risk 
of bias (25).
For aortic aneurysm patients, only one RCT is available, which 
showed a high efficacy with 3 years follow-up. However, this study 
was poorly powered, non-blinded, and scored low in the Jadad 
scale (2). Moreover, no information on sources of funding and 
protocol registration was provided, and therefore, the risk of bias 
cannot be assessed.
The currently available evidence is not strong enough to make 
any statements regarding the optimal mesh position (intraperito-
neal, retro-muscular, or onlay) in case a prophylactic biological 
mesh is used. Also, the different meshes used in the studies 
(non-cross-linked human origin; non-cross-linked porcine small 
intestinal submucosa; cross-linked bovine pericardium) might 
have an important impact on the outcome.
On the contrary, the Level of Evidence on the efficacy of 
prophylactic synthetic non-absorbable mesh (all polypropyl-
ene) in high-risk patients currently is high, with 8 published 
RCTs encompassing 727 patients with a follow-up of at least 
12 months (1, 4–6, 15–18). Moreover, the safety of prophylactic 
retro-muscular or onlay meshes in clean or clean-contaminated 
surgery is shown in 9 published RCTs encompassing 1207 
patients (1, 3–6, 15–18).
No comparative studies were found comparing biological 
mesh with synthetic non-absorbable meshes for the prevention 
of IHs. There is a study ongoing at the Vall d’Hebron Hospital, 
Universidad Autónoma de Barcelona on the prevention of IHs 
from midline laparotomies using an absorbable synthetic mesh 
(Bio-A, WL Gore & Ass, USA), PREBIOUS trial.2
2 www.ClinicalTrials.gov NCT02208557 
FiGURe 2 | Forest plots and risk of bias assessment of randomized studies on the prevention of incisional hernias by biological mesh reinforcement.
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Stoma Reversal wound
Overall, the Level of Evidence on the efficacy of biological mesh to 
prevent IHs of stoma reversal wounds is very low. Currently, the 
only study providing evidence is a matched case–control study, 
showing a lower IH rate at 1 year. This study is a pilot study for 
an RCT that is planned in France, the MEMBO trial3 (27). The 
small pilot study by Banghu et al. is part of a large project, the 
ROCSS study, which is a properly powered multicenter RCT from 
3 www.ClinicalTrials.gov NCT02576184 
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the University of Birmingham4 (26). This study compares the 
technique described in the pilot study with sutured closure of the 
stoma wound and has now included 790 patients, and the follow-
up is ongoing. Furthermore, a study from the Vall d’Hebron 
Hospital (Universidad Autónoma de Barcelona), ILEOCLOSE 
study,5 will investigate in a RCT the application of prophylactic 
mesh reinforcement of closure of temporary diverting ileostomy 
with an absorbable synthetic mesh (Bio-A) in 120 patients.
CONCLUSiON
So far, there is no solid evidence on the effectiveness of pro-
phylactic non-permanent absorbable biological or biosynthetic 
mesh for the closure of midline laparotomies or reinforcement 
of a stoma reversal site. There is no evidence that, in this setting, 
a non-permanent absorbable biological or biosynthetic mesh 
should be preferred to synthetic non-absorbable mesh, both in 
clean or clean-contaminated surgery.
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APPeNDiX
Addendum 1
Search strategy used for a systematic literature review on 
prevention of incisional hernias with mesh. A computerized 
search was performed within 12 databases (Embase, Medline, 
Web-of-Science, Scopus, Cochrane, Cinahl, Pubmed publisher, 
Lilacs, Scielo, ScienceDirect, ProQuest, Google scholar) on June 
25th 2015.
Embase.com 839
('surgical mesh'/exp OR (mesh* OR 4DDOME OR AIGISRx 
OR AlloDerm OR AlloMax OR 'Bard Composix EX' OR 
'BIO-A Tissue Reinforcement prosthesis' OR CollaMend OR 
DermaMatrix OR DualMesh OR 'Evolution P3EM' OR FasLata 
OR FlexHD OR FortaGen OR 'IntePro Lite' OR InteXen OR 
NEOVEIL OR 'Parietex composite' OR Pelvicol OR Pelvisoft 
OR Pelvitex OR PerFix OR 'Peri-Strips Dry' OR PeriGuard 
OR Permacol OR Physiomesh OR SeamGuard OR Strattice 
OR Surgisis OR 'TiLoop Bra' OR Timesh OR Tutomesh OR 
Tutopatch OR Ultrapro OR Ventralex OR Veritas OR Vivosorb 
OR Vypro OR X-Repair OR XenMatrix):ab,ti) AND (preven-
tion/exp OR prevention:lnk OR (prevent* OR protect* OR 
prophyla*):ab,ti) AND ('incisional hernia'/exp OR 'abdominal 
wall hernia'/de OR 'abdominal wall defect'/de OR 'abdominal 
surgery'/de OR 'abdominal wall closure'/de OR laparotomy/exp 
OR 'abdominal wall'/de OR (((incision* OR cicatri* OR scar* 
OR ventral*) NEAR/3 (herni*)) OR ((abdominal* OR transab-
dominal*) NEAR/3 (surger* OR clos* OR defect* OR wall*)) 
OR laparotom* OR (midline NEAR/3 incision*)):ab,ti) NOT 
([animals]/lim NOT [humans]/lim)
Medline (ovid) 490
("surgical mesh"/OR (mesh* OR 4DDOME OR AIGISRx OR 
AlloDerm OR AlloMax OR "Bard Composix EX" OR "BIO-A Tissue 
Reinforcement prosthesis" OR CollaMend OR DermaMatrix 
OR DualMesh OR "Evolution P3EM" OR FasLata OR FlexHD 
OR FortaGen OR "IntePro Lite" OR InteXen OR NEOVEIL OR 
"Parietex composite" OR Pelvicol OR Pelvisoft OR Pelvitex OR 
PerFix OR "Peri-Strips Dry" OR PeriGuard OR Permacol OR 
Physiomesh OR SeamGuard OR Strattice OR Surgisis OR "TiLoop 
Bra" OR Timesh OR Tutomesh OR Tutopatch OR Ultrapro OR 
Ventralex OR Veritas OR Vivosorb OR Vypro OR X-Repair OR 
XenMatrix).ab,ti.) AND ("Primary Prevention"/OR "prevention 
and control".xs. OR (prevent* OR protect* OR prophyla*).ab,ti.) 
AND ("Hernia, Ventral"/OR "Hernia, Abdominal"/OR abdomen/
su OR laparotomy/OR "abdominal wall"/OR (((incision* OR cic-
atri* OR scar* OR ventral*) ADJ3 (herni*)) OR ((abdominal* OR 
transabdominal*) ADJ3 (surger* OR clos* OR defect* OR wall*)) 
OR laparotom* OR (midline ADJ3 incision*)).ab,ti.) NOT (exp 
animals/NOT humans/)
Cochrane 30
((mesh* OR 4DDOME OR AIGISRx OR AlloDerm OR AlloMax 
OR 'Bard Composix EX' OR 'BIO-A Tissue Reinforcement 
prosthesis' OR CollaMend OR DermaMatrix OR DualMesh OR 
'Evolution P3EM' OR FasLata OR FlexHD OR FortaGen OR 
'IntePro Lite' OR InteXen OR NEOVEIL OR 'Parietex composite' 
OR Pelvicol OR Pelvisoft OR Pelvitex OR PerFix OR 'Peri-Strips 
Dry' OR PeriGuard OR Permacol OR Physiomesh OR SeamGuard 
OR Strattice OR Surgisis OR 'TiLoop Bra' OR Timesh OR 
Tutomesh OR Tutopatch OR Ultrapro OR Ventralex OR Veritas 
OR Vivosorb OR Vypro OR X-Repair OR XenMatrix):ab,ti) 
AND ((prevent* OR protect* OR prophyla*):ab,ti) AND ((((inci-
sion* OR cicatri* OR scar* OR ventral*) NEAR/3 (herni*)) OR 
((abdominal* OR transabdominal*) NEAR/3 (surger* OR clos* 
OR defect* OR wall*)) OR laparotom* OR (midline NEAR/3 
incision*)):ab,ti)
Web-of-science 474
TS  =  (((mesh* OR 4DDOME OR AIGISRx OR AlloDerm 
OR AlloMax OR "Bard Composix EX" OR "BIO-A Tissue 
Reinforcement prosthesis" OR CollaMend OR DermaMatrix 
OR DualMesh OR "Evolution P3EM" OR FasLata OR FlexHD 
OR FortaGen OR "IntePro Lite" OR InteXen OR NEOVEIL 
OR "Parietex composite" OR Pelvicol OR Pelvisoft OR Pelvitex 
OR PerFix OR "Peri-Strips Dry" OR PeriGuard OR Permacol 
OR Physiomesh OR SeamGuard OR Strattice OR Surgisis 
OR "TiLoop Bra" OR Timesh OR Tutomesh OR Tutopatch 
OR Ultrapro OR Ventralex OR Veritas OR Vivosorb OR 
Vypro OR X-Repair OR XenMatrix)) AND ((prevent* OR 
protect* OR prophyla*)) AND ((((incision* OR cicatri* OR 
scar* OR ventral*) NEAR/3 (herni*)) OR ((abdominal* OR 
transabdominal*) NEAR/3 (surger* OR clos* OR defect* OR 
wall*)) OR laparotom* OR (midline NEAR/3 incision*))) NOT 
((animal* OR rat OR rats OR mouse OR mice OR murine OR 
rabbit* OR rodent* OR pig OR sus OR swine* OR porcine 
OR monkey* OR dog OR sheep OR ovine) NOT (human* OR 
patient*)))
Scopus 697
TITLE-ABS-KEY(((mesh* OR 4DDOME OR AIGISRx OR 
AlloDerm OR AlloMax OR "Bard Composix EX" OR "BIO-A Tissue 
Reinforcement prosthesis" OR CollaMend OR DermaMatrix 
OR DualMesh OR "Evolution P3EM" OR FasLata OR FlexHD 
OR FortaGen OR "IntePro Lite" OR InteXen OR NEOVEIL OR 
"Parietex composite" OR Pelvicol OR Pelvisoft OR Pelvitex OR 
PerFix OR "Peri-Strips Dry" OR PeriGuard OR Permacol OR 
Physiomesh OR SeamGuard OR Strattice OR Surgisis OR "TiLoop 
Bra" OR Timesh OR Tutomesh OR Tutopatch OR Ultrapro OR 
Ventralex OR Veritas OR Vivosorb OR Vypro OR X-Repair OR 
XenMatrix)) AND ((prevent* OR protect* OR prophyla*)) AND 
((((incision* OR cicatri* OR scar* OR ventral*) W/3 (herni*)) OR 
((abdominal* OR transabdominal*) W/3 (surger* OR clos* OR 
defect* OR wall*)) OR laparotom* OR (midline W/3 incision*))) 
AND NOT ((animal* OR rat OR rats OR mouse OR mice OR 
murine OR rabbit* OR rodent* OR pig OR sus OR swine* OR 
porcine OR monkey* OR dog OR sheep OR ovine) AND NOT 
(human* OR patient*)))
cinahl (ebsco) 23
(MH "surgical mesh + " OR (mesh* OR 4DDOME OR AIGISRx 
OR AlloDerm OR AlloMax OR "Bard Composix EX" OR 
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"BIO-A Tissue Reinforcement prosthesis" OR CollaMend OR 
DermaMatrix OR DualMesh OR "Evolution P3EM" OR FasLata 
OR FlexHD OR FortaGen OR "IntePro Lite" OR InteXen OR 
NEOVEIL OR "Parietex composite" OR Pelvicol OR Pelvisoft 
OR Pelvitex OR PerFix OR "Peri-Strips Dry" OR PeriGuard 
OR Permacol OR Physiomesh OR SeamGuard OR Strattice 
OR Surgisis OR "TiLoop Bra" OR Timesh OR Tutomesh 
OR Tutopatch OR Ultrapro OR Ventralex OR Veritas OR 
Vivosorb OR Vypro OR X-Repair OR XenMatrix)) AND (MH 
"Preventive Health Care" OR MW prevention OR (prevent* 
OR protect* OR prophyla*)) AND (MH "Hernia, Abdominal" 
OR MH abdomen/su OR MH laparotomy OR (((incision* OR 
cicatri* OR scar* OR ventral*) N3 (herni*)) OR ((abdominal* 
OR transabdominal*) N3 (surger* OR clos* OR defect* OR 
wall*)) OR laparotom* OR (midline N3 incision*))) NOT (MH 
animals + NOT humans +)
Pubmed publisher 14
("surgical mesh"[mh] OR (mesh*[tiab] OR 4DDOME OR 
AIGISRx OR AlloDerm OR AlloMax OR "Bard Composix EX" 
OR "BIO-A Tissue Reinforcement prosthesis" OR CollaMend 
OR DermaMatrix OR DualMesh OR "Evolution P3EM" OR 
FasLata OR FlexHD OR FortaGen OR "IntePro Lite" OR 
InteXen OR NEOVEIL OR "Parietex composite" OR Pelvicol 
OR Pelvisoft OR Pelvitex OR PerFix OR "Peri-Strips Dry" OR 
PeriGuard OR Permacol OR Physiomesh OR SeamGuard 
OR Strattice OR Surgisis OR "TiLoop Bra" OR Timesh OR 
Tutomesh OR Tutopatch OR Ultrapro OR Ventralex OR Veritas 
OR Vivosorb OR Vypro OR X-Repair OR XenMatrix)) AND 
("Primary Prevention"[mh] OR "prevention and control"[sh] OR 
(prevent*[tiab] OR protect*[tiab] OR prophyla*[tiab])) AND 
("Hernia, Ventral"[mh] OR "Hernia, Abdominal"[mh] OR abdo-
men/su[mh] OR laparotomy[mh] OR "abdominal wall"[mh] 
OR (((incision*[tiab] OR cicatri*[tiab] OR scar*[tiab] OR 
ventral*[tiab]) AND (herni*[tiab])) OR ((abdominal*[tiab] OR 
transabdominal*[tiab]) AND (surger*[tiab] OR clos*[tiab] OR 
defect*[tiab] OR wall*[tiab])) OR laparotom*[tiab] OR (midline 
AND incision*[tiab]))) NOT (animals[mh] NOT humans[mh]) 
AND publisher[sb]
Google scholar
Mesh|meshes prevention|preventive|protective|protection| 
prophylactic|prophylaxis "incisioal|cicatrical|scar|ventral hernia"| 
"abdominal|transabdominal surgery|closure|defect|wall"| 
laparotomy|"midline incision" -animal -animals -rats -mice
Lilacs 18
Scielo 8
(Mesh*) AND (prevent* OR protect* OR prophyla*) AND 
("incisional hernia" OR "cicatrical hernia" OR "scar hernia" OR " 
ventral hernia" OR "abdominal hernia" OR "abdominal surgery" 
OR "abdominal closure" OR "abdominal defect" OR "abdominal 
wall" OR laparotom* OR "midline incision")
ScienceDirect 92
(Mesh*) AND (prevent* OR protect* OR prophyla*) AND 
("incisional hernia" OR "cicatrical hernia" OR "scar hernia" OR " 
ventral hernia" OR "abdominal hernia" OR "abdominal surgery" 
OR "abdominal closure" OR "abdominal defect" OR "abdominal 
wall" OR laparotom* OR "midline incision") AND TOPIC (inci-
sional hernia)
ProQuest 9
(ti(Mesh*) OR ab(Mesh*)) AND (ti(prevent* OR protect* OR 
prophyla*) OR ab(prevent* OR protect* OR prophyla*)) AND 
(ti("incisional hernia" OR "cicatrical hernia" OR "scar hernia" OR 
" ventral hernia" OR "abdominal hernia" OR "abdominal surgery" 
OR "abdominal closure" OR "abdominal defect" OR "abdominal 
wall" OR laparotom* OR "midline incision") OR ab("incisional 
hernia" OR "cicatrical hernia" OR "scar hernia" OR " ventral 
hernia" OR "abdominal hernia" OR "abdominal surgery" OR 
"abdominal closure" OR "abdominal defect" OR "abdominal wall" 
OR laparotom* OR "midline incision"))
